Charles River Laboratories Stock Today
| CRL Stock | USD 163.50 2.30 1.39% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Charles River is selling for 163.50 as of the 18th of January 2025. This is a 1.39 percent down since the beginning of the trading day. The stock's lowest day price was 163.07. Charles River has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on December 6, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Charles River Labora's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of June 2000 | Category Healthcare | Classification Health Care |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. Charles River Laboratories International, Inc. The company has 51.14 M outstanding shares of which 2.26 M shares are currently shorted by investors with about 4.17 days to cover. More on Charles River Laboratories
Moving against Charles Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Charles Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | James JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Comet Resources Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP 500 Index, Dow Jones Biotechnology, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCharles River can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Charles River's financial leverage. It provides some insight into what part of Charles River's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Charles River Laboratories (CRL) is traded on New York Stock Exchange in USA. It is located in 251 Ballardvale Street, Wilmington, MA, United States, 01887 and employs 20,400 people. Charles River is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 8.89 B. Charles River Labora runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 51.14 M outstanding shares of which 2.26 M shares are currently shorted by investors with about 4.17 days to cover.
Charles River Laboratories has about 233.91 M in cash with 683.9 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96.
Check Charles River Probability Of Bankruptcy
Ownership AllocationThe majority of Charles River Laboratories outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Charles River Labora to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Charles River. Please pay attention to any change in the institutional holdings of Charles River Laboratories as this could imply that something significant has changed or is about to change at the company. Please note that on December 6, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Charles River Labora's common stock.
Check Charles Ownership Details
Charles Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-09-30 | 980.8 K | |
| Mackenzie Investments | 2024-09-30 | 971.3 K | |
| Ariel Investments, Llc | 2024-09-30 | 897.7 K | |
| Amvescap Plc. | 2024-09-30 | 883 K | |
| Southpoint Capital Advisors Lp | 2024-09-30 | 670 K | |
| Franklin Resources Inc | 2024-09-30 | 664.5 K | |
| Sei Investments Co | 2024-09-30 | 635 K | |
| Wells Fargo & Co | 2024-09-30 | 551.8 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 527.5 K | |
| Vanguard Group Inc | 2024-09-30 | 6.1 M | |
| Blackrock Inc | 2024-09-30 | 4.2 M |
Charles River Historical Income Statement
Charles Stock Against Markets
Charles River Corporate Directors
| Robert Bertolini | Independent Director | Profile | |
| George Milne | Lead Independent Director | Profile | |
| George Llado | Independent Director | Profile | |
| Nancy Andrews | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Charles River Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Charles River. If investors know Charles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Charles River listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.21) | Earnings Share 7.64 | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Charles River Labora is measured differently than its book value, which is the value of Charles that is recorded on the company's balance sheet. Investors also form their own opinion of Charles River's value that differs from its market value or its book value, called intrinsic value, which is Charles River's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Charles River's market value can be influenced by many factors that don't directly affect Charles River's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Charles River's value and its price as these two are different measures arrived at by different means. Investors typically determine if Charles River is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Charles River's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.